Business Context and Reporting Period
This Form 8-K Current Report was filed by Amphastar Pharmaceuticals, Inc. on March 14, 2019, regarding events occurring on March 8, 2019. The filing addresses changes to the Company's Board of Directors ahead of the 2019 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
- Director Departure: Dr. Stephen Shohet, a Class III member of the Board of Directors, notified the Board on March 8, 2019, that he will not stand for re-election when his term expires at the 2019 Annual Meeting. He will continue to serve until that date.
- Reason for Departure: Dr. Shohet's decision is not the result of any disagreement with management or the Board, nor is it related to the Company's operations, policies, or practices.
- Director Nomination: The Nomination Committee nominated Ms. Diane G. Gerst to fill the vacancy created by Dr. Shohet's departure. She is a former Executive Vice President of Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements cautioning that actual results may differ materially from current expectations due to various risks and uncertainties. The Company disclaims any obligation to update these statements. No specific business outlook, guidance, or new risk factors were disclosed in this report.
Key Facts for Investor Verification
- Verify the final composition of the Board of Directors following the 2019 Annual Meeting.
- Review the Company's 2019 Proxy Statement for detailed biographical information on Ms. Diane G. Gerst and the director nomination process.
- Confirm that Dr. Shohet's departure remains unrelated to any undisclosed operational or governance disputes.